NeoGenomics Q2 revenue up 10% but misses estimates as  pharma revenue drags

NeoGenomics

29/07/2025 12:22

Overview

NeoGenomics Q2 revenue up 10% to $181 mln, missing analyst expectations

Net loss increased 142% to $45 mln due to $20 mln impairment charges

Completed Pathline acquisition in April, boosting clinical revenue growth

Outlook

NeoGenomics sees 2025 revenue between $720 mln and $726 mln

Company expects 2025 net loss between $108 mln and $116 mln

NeoGenomics anticipates 2025 adjusted EBITDA of $41 mln to $44 mln

Company preparing for the commercial launch of PanTracer Liquid Biopsy

Result Drivers

CLINICAL REVENUE - Clinical revenue grew 16% due to improved average unit price, record volumes, and 23% growth in NGS, per CEO Tony Zook; Clinical revenue grew 13% excluding Pathline

PHARMA REVENUE PRESSURE - Continued pressure in pharma revenue affected overall performance, beyond initial assumptions

LAUNCH DELAY - Delay in commercial launch of PanTracer Liquid Biopsy impacted expected NGS revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$181 mln
$182.70 mln (14 Analysts)
Q2 Adjusted Net Income
-$3.60 mln
Q2 Net Income
-$45 mln
Q2 Adjusted EBITDA
$10.70 mln
Q2 Gross Profit
$77 mln
Q2 Operating Expenses
$125 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Neogenomics Inc is $12.00, about 46.2% above its July 28 closing price of $6.46

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 44 three months ago

Press Release: ID:nBw16XB2ga

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)